Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Corneal refractive power modulation refers to the alteration of the cornea’s ability to bend (refract) light, typically induced by interventions such as orthokeratology or low-dose atropine therapy in myopic children. It is measured by changes in corneal topography and quantified by metrics such as maximal relative corneal refractive power (mRCRP); a higher amplitude of modulation is associated with more effective myopia control. Corneal refractive power modulation is not a molecular entity but describes the outcome of physical and geometric changes in the cornea, which may be predictive for therapies aiming to slow myopic progression. Therefore, it is not considered a canonical therapeutic target like a receptor or enzyme.
Changes corneal shape to alter refractive power and peripheral focus (orthokeratology) Modest effects on corneal and lens curvature (atropine)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Corneal refractive power modulation.